Resources VIDEOS 00:48 Are your T2D patients on the right DPP4i dose? 00:38 DPP4i - Proven efficacy with no dose reduction 00:27 DPP4i – What efficacy to expect? 00:54 Efficacy, Safety, Simplicity all in one DPP4i 01:22 JENTADUETO® dosing information 00:38 Renally impaired patients - Are they on the right dose? 00:21 Restricting TRAJENTA® to only renally impaired patients 02:30 EMPA-REG Outcome Results - Video 01:32 High Residual CV Risk How does Nintedanib benefit patients in preserving lung function? 02:44 Effect On Honeycombing Efficacy 03:17 Efficacy with Concomitant Emphysema 00:57 Expert Opinion 03:20 Mechanism of Action 05:58 Survival Analysis 09:33 Patients Subgroup Analysis 02:03 Why was the data of the INPULSIS® and TOMORROW trials pooled? 03:20 Value Proposition Load more Clinical studies Carmelina Cardiovascular Results - No HHF Carmelina Cardiovascular Results Carmelina Kidney Results - Lower Risk Of Albuminurea Carmelina Kidney Results Safety Trajenta Efficacy vs Trajenta Efficacy Regardless of Age Trajenta Efficacy With Same Dose In Severe Renal Impairment Trajenta Efficacy With Same Dose Regardless of Kidney Function Trajenta Simplicity of Dosing Trajenta Simplicity Trajenta Efficacy up to 104 Weeks vs Glimepride Trajenta Efficacy Added To Metformin Trajenta Efficacy Regardless of BMI Trajenta Efficacy vs Pioglitazone Carmelina Study Design Carmelina Study Inclusion Criteria Carmelina Trial Overview EMPA-REG OUTCOME Results EMPA-REG Outcome Study Design Jardiance® Prescribing Information Synjardy® Prescribing Information How does Nintedanib benefit patients in preserving lung function? How does dosing and administration of Nintedanib help compliance of IPF patients? Is honeycombing in an HRCT, the sole detector of IPF? Load more